查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
RNA治療臨床試驗市場規模、佔有率、趨勢分析報告：按模式、階段、治療領域、地區、細分趨勢，2023-2030年
市場調查報告書
商品編碼
1321424

RNA治療臨床試驗市場規模、佔有率、趨勢分析報告：按模式、階段、治療領域、地區、細分趨勢，2023-2030年

RNA Therapy Clinical Trials Market Size, Share & Trends Analysis Report By Modality, By Phase, By Therapeutic Areas (Rare Diseases, Anti-infective, Anticancer, Neurological), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

RNA治療臨床試驗市場成長和趨勢

Grand View Research 的最新報告顯示，到2030年，全球 RNA 治療臨床試驗市場預計將達到 35 億美元。

預計2023年至2030年該市場將以3.84%的年複合成長率成長。新興市場的成長是由生物技術和製藥公司的升級推動的，感染疾病和罕見疾病負擔的增加、基於 RNA 的 COVID-19 疫苗成功率的提高、法規的批准和個體化藥物的需求推動推動市場成長。

此外，RNA療法是有前途的疾病治療或預防方法，導致多項RNA臨床試驗的增加。此外，對不同類型RNA及其治療各種人類疾病和病症的能力的長期研究工作帶來了強勁的市場需求。此外，RNA 療法（其中 RNA 本身充當藥物或靶點）的潛在好處是針對罕見和難以治療的疾病開發新藥的創新方法。

在全球範圍內，感染疾病和罕見病仍然是導致死亡的主要原因，生物技術和製藥公司越來越關注開發新藥。因此，基於RNA的治療技術創新不斷進步，對RNA治療的臨床試驗產生了巨大的需求。此外，罕見疾病仍然是 RNA 療法最具針對性的治療領域。

此外，根據美國食品藥物管理局(FDA) 的資料，截至2022年 12月，超過 7,000 種罕見疾病影響了美國超過3000 萬人；根據歐盟委員會的資料，截至2023年2月，超過30 種罕見疾病影響了美國超過3000 萬人。美國有 100 萬人受到罕見疾病的影響。全球有多達 3600 萬人患有罕見疾病。歐盟有 6000 多種不同的罕見疾病。同樣，加深對 RNA 功能及其在疾病預防中的作用的了解促進 RNA 的各種應用。

COVID-19 大流行嚴重影響了 RNA 治療臨床試驗市場的成長。製藥和生物技術公司突然關注疫苗開發和研發活動無疑擾亂了世界各地的 RNA 臨床試驗。然而，研究人員對基於 RNA 的 COVID-19 疫苗開發的興趣日益濃厚，支持了市場的積極成長。此外，人們對將 RNA 用於其他感染疾病和腫瘤適應症也很感興趣。這些要素推動市場成長。

此外，主要參與企業採取聯盟、協議、聯合研究和市場啟動等戰略，以擴大其全球影響力和產品系列。例如，2021年 3月，IQVIA 公司宣布與 Janssen Research & Development, LLC 合作開展 COVID-19 疫苗 3 期臨床試驗。該考試結合了虛擬監督、遠端醫療技術和數位病人參與策略，以支持遠程和現場考試。

RNA 治療臨床試驗市場報告亮點

  • 信使RNA細分市場在2022年佔據最大的銷售佔有率，為35.7%，因為基因表現領域的研究人員數量不斷增加，技術進步促進了該細分市場的成長。
  • II 期細分市場在 RNA 治療臨床試驗市場佔據主導地位，2022年收入佔有率為 41.3%。 RNA 治療的有效性和 RNA 臨床試驗的安全性預計將推動細分市場的成長。
  • 2022年，罕見病細分市場佔據主導地位，佔銷售佔有率的21.8%。成長的主要要素是不同類型罕見疾病負擔的增加。市場參與企業的研發支出也是市場成長的驅動力。
  • 2022年，北美地區的銷售佔有率最大，為36.6%。成熟市場參與者的存在、罕見疾病負擔的增加、RNA 研究活動的活性化以及臨床試驗數量的增加推動該地區的成長。
  • 此外，持續的技術創新和不斷增加的臨床研究和試驗推動該地區的市場成長。例如，2022年12月，Moderna和默克提到了mRNA-4157/V940的2b期KEYNOTE-942/mRNA-4157-P201試驗，這是一種與KEYTRUDA聯合使用的個體化mRNA癌症疫苗。這是一種 mRNA 癌症疫苗，用於治療 III/IV 期黑色素瘤患者。
  • 主導市場的一些主要企業包括 IQVIA、Laboratory Corporation of America Holdings、ICON Plc、Charles River Laboratories International, Inc.、PPD Inc.、Syneos Health、Medpace Holdings, Inc.、Novotech、PAREXEL International Corp.、Veristat, LLC.。

目錄

第1章 調查方法和範圍

  • 資訊採購
  • 資訊或資料分析
  • 市場範圍和細分定義
  • 市場模式

第2章 執行摘要

第3章 市場變量、趨勢和範圍

  • 市場區隔和範圍
  • 市場體系預測
    • 母市場預測
    • 相關/輔助市場預測
  • 市場趨勢及展望
  • 市場動態
  • 市場促進因素分析
  • 市場抑制因素分析
  • 營商環境分析
    • SWOT分析
    • 波特五力分析
  • COVID-19 影響分析

第4章 模態業務分析

  • RNA治療臨床試驗市場：模態變異分析
  • RNA干擾
  • 反義療法
  • 信使核糖核酸
  • 寡核苷酸，非反義，非RNAi

第5章 臨床試驗階段業務分析

  • RNA治療臨床試驗市場：臨床試驗階段變異分析
  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

第6章 治療領域業務分析

  • RNA治療臨床試驗市場：治療領域波動分析
  • 罕見疾病
  • 抗感染疾病
  • 抗癌劑
  • 神經系統
  • 消化器官系統/代謝系統
  • 肌肉骨骼系統
  • 心血管、呼吸系統
  • 情懷
  • 其他

第7章 區域業務分析

  • 2022年和2030年按地區分類的 RNA 治療臨床試驗市場佔有率
  • 北美
    • 2018-2030年北美RNA治療臨床試驗市場
    • 美國
    • 加拿大
  • 歐洲
    • 2018-2030年歐洲RNA療法臨床試驗市場
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 瑞典
    • 挪威
    • 丹麥
  • 亞太地區
    • 亞太地區RNA治療臨床試驗市場，2018-2030
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 拉丁美洲RNA治療臨床試驗市場，2018-2030
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東、非洲
    • 2018-2030年中東和非洲RNA治療臨床試驗市場
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭形勢

  • 公司分類
  • 戰略規劃
    • 併購
    • 合作
    • 新產品發布
  • 參與企業概況
    • IQVIA
    • ICON Plc
    • Laboratory Corporation of America Holdings
    • Charles River Laboratories International, Inc.
    • PAREXEL International Corp.
    • Syneos Health
    • Medpace Holdings, Inc.
    • PPD Inc.
    • Novotech
    • Veristat, LLC.
Product Code: GVR-4-68040-100-2

RNA Therapy Clinical Trials Market Growth & Trends

The global RNA therapy clinical trials market size is expected to reach USD 3.5 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 3.84% from 2023 to 2030. The growth of the market in emerging countries is due to escalating biotechnology and pharmaceutical companies, the increasing burden of infectious and rare diseases, the growing success rate of RNA-based COVID-19 vaccines, regulatory approval, and demand for personalized medicines drive the market growth.

Besides, RNA therapy acts as a promising therapeutic approach for the treatment or prevention of diseases leading to a rise in several RNA clinical trials. Additionally, long-term research activities on various types of RNAs, and the ability of RNA to treat various human diseases and disorders have led to strong demand for the market. Also, the potential benefit of RNA therapy wherein RNA itself serves as either a drug or a target provides acts as an innovative approach for developing new drugs for rare or difficult-to-treat diseases.

Globally, infectious diseases and rare diseases remain the leading cause of death, which has gained the increased attention of biotechnology and pharmaceutical companies to develop new drugs. This led to the rise in the innovation of RNA-based therapy creating immense requirements for RNA therapy clinical trials. Additionally, rare diseases remain the top targeted therapeutic area by RNA therapies.

Furthermore, according to the US Food & Drug Administration, in December 2022, over 7,000 rare diseases affected more than 30 million people in the U.S. whereas according to European Commission as of February 2023, up to 36 million European population live with a rare disease. There are 6000+ distinct rare diseases in the EU. Likewise, the increasing understanding of RNA functions and their roles in disease prevention has promoted various RNAs application.

The COVID-19 pandemic has greatly impacted the growth of the RNA therapy clinical trials market. The sudden focus of pharmaceutical and biotechnology companies on the development of the vaccine, research, and development activities had certainly disrupted the RNA clinical trials across the globe. However, the increasing interest of researchers to develop an RNA-based COVID-19 vaccine has supported the market with positive growth. Additionally, it has also sparked an interest in RNA use against other infectious diseases and oncology indications. These factors drive the growth of the market.

Furthermore, the key participants engage in strategies such as partnerships, agreements, collaborations, and launches, to expand their global footprints and product portfolio. For instance, in March 2021, IQVIA Company announced the collaboration with Janssen Research & Development, LLC for Phase 3 COVID-19 vaccine clinical trials. The studies will support both remote and on-site studies through a mix of virtual oversight, telehealth technologies, and digital patient engagement strategies.

RNA Therapy Clinical Trail Market Report Highlights

  • The messenger RNA segment held the largest revenue share of 35.7% in 2022 owing to increased researchers' study in gene expression, technology advancement has contributed to the segment growth
  • The Phase II segment dominated the RNA therapy clinical trials market with a revenue share of 41.3% in 2022. The effectiveness of RNA therapy and the safety of RNA clinical trials will drive segment growth
  • In 2022, the rare diseases segment dominated the market and accounted for a revenue share of 21.8%. The key factors contributing to the growth include the growing burden of various types of rare diseases. Also, R&D expenditures made by market players drive the market growth
  • North America held the largest revenue share of 36.6% in 2022. The presence of well-established market players, the increasing burden of rare diseases, growing research activities on RNA, rising number of clinical trials drive the regional growth
  • Additionally, constant innovation and an emerging number of clinical studies and trials drive the market growth in the region. For instance, in December 2022, Moderna & Merck mentioned the phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940 a personalized mRNA cancer vaccine with KEYTRUDA combination. It is an mRNA cancer vaccine for melanoma stage III/IV patient treatment
  • Key players dominating the market include IQVIA; Laboratory Corporation of America Holdings; ICON Plc; Charles River Laboratories International, Inc.; PPD Inc.; Syneos Health; Medpace Holdings, Inc.; Novotech; PAREXEL International Corp.; and Veristat, LLC

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Information Procurement
  • 1.2. Information or Data Analysis
  • 1.3. Market Scope & Segment Definition
  • 1.4. Market Model

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends and Outlook
  • 3.4. Market Dynamics
  • 3.5. Market Driver Analysis
  • 3.6. Market Restraint Analysis
  • 3.7. Business Environment Analysis
    • 3.7.1. SWOT Analysis
    • 3.7.2. Porter's Five Forces Analysis
  • 3.8. COVID-19 Impact Analysis

Chapter 4. Modality Business Analysis

  • 4.1. RNA therapy clinical trials Market: Modality Movement Analysis
  • 4.2. RNA interference
    • 4.2.1. RNA interference Market, 2018 - 2030 (USD Million)
  • 4.3. Antisense therapy
    • 4.3.1. Antisense therapy Market, 2018 - 2030 (USD Million)
  • 4.4. Messenger RNA
    • 4.4.1. Messenger RNA Market, 2018 - 2030 (USD Million)
  • 4.5. Oligonucleotide, non-antisense, non-RNAi
    • 4.5.1. Oligonucleotide, non-antisense, non-RNAi Market, 2018 - 2030 (USD Million)

Chapter 5. Clinical Trials Phase Business Analysis

  • 5.1. RNA therapy clinical trials Market: Clinical Trials Phase Movement Analysis
  • 5.2. Phase I
    • 5.2.1. Phase I Market, 2018 - 2030 (USD Million)
  • 5.3. Phase II
    • 5.3.1. Phase II Market, 2018 - 2030 (USD Million)
  • 5.4. Phase III
    • 5.4.1. Phase III Market, 2018 - 2030 (USD Million)
  • 5.5. Phase IV
    • 5.5.1. Phase IV Market, 2018 - 2030 (USD Million)

Chapter 6. Therapeutic Areas Business Analysis

  • 6.1. RNA therapy clinical trials Market: Therapeutic Areas Movement Analysis
  • 6.2. Rare Diseases
    • 6.2.1. Rare Diseases Market, 2018 - 2030 (USD Million)
  • 6.3. Anti-infective
    • 6.3.1. Anti-infective Market, 2018 - 2030 (USD Million)
  • 6.4. Anticancer
    • 6.4.1. Anticancer Market, 2018 - 2030 (USD Million)
  • 6.5. Neurological
    • 6.5.1. Neurological Market, 2018 - 2030 (USD Million)
  • 6.6. Alimentary/Metabolic
    • 6.6.1. Alimentary/Metabolic Market, 2018 - 2030 (USD Million)
  • 6.7. Musculoskeletal
    • 6.7.1. Musculoskeletal Market, 2018 - 2030 (USD Million)
  • 6.8. Cardiovascular Respiratory
    • 6.8.1. Cardiovascular Respiratory Market, 2018 - 2030 (USD Million)
  • 6.9. Sensory
    • 6.9.1. Sensor Market, 2018 - 2030 (USD Million)
  • 6.10. Others
    • 6.10.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. RNA therapy clinical trials Market Share By Region, 2022 & 2030
  • 7.2. North America
    • 7.2.1. North America RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. Key Country Dynamics
      • 7.2.2.2. Regulatory Framework
      • 7.2.2.3. Competitive Scenario
      • 7.2.2.4. U.S. RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Regulatory Framework
      • 7.2.3.3. Competitive Scenario
      • 7.2.3.4. Canada RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. UK RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Germany RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Competitive Scenario
      • 7.3.4.3. France RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Key Country Dynamics
      • 7.3.5.2. Competitive Scenario
      • 7.3.5.3. Italy RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Key Country Dynamics
      • 7.3.6.2. Competitive Scenario
      • 7.3.6.3. Spain RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.3.7. Sweden
      • 7.3.7.1. Key Country Dynamics
      • 7.3.7.2. Competitive Scenario
      • 7.3.7.3. Sweden RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.3.8. Norway
      • 7.3.8.1. Key Country Dynamics
      • 7.3.8.2. Competitive Scenario
      • 7.3.8.3. Norway RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.3.9. Denmark
      • 7.3.9.1. Key Country Dynamics
      • 7.3.9.2. Competitive Scenario
      • 7.3.9.3. Denmark RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Japan RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. China RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. India RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Competitive Scenario
      • 7.4.5.3. Australia RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.4.6. South Korea
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Competitive Scenario
      • 7.4.6.3. South Korea RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Competitive Scenario
      • 7.4.7.3. Thailand RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Brazil RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Mexico RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.5.4. Argentina
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Argentina RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
  • 7.6. MEA
    • 7.6.1. MEA RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. South Africa RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Saudi Arabia RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. UAE RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Kuwait RNA therapy clinical trials Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
    • 8.2.1. Merger& Acquisition
    • 8.2.2. Collaborations
    • 8.2.3. New Product Launch
  • 8.3. Participant's overview
    • 8.3.1. IQVIA
      • 8.3.1.1. Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Product Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. ICON Plc
      • 8.3.2.1. Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Product Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. Laboratory Corporation of America Holdings
      • 8.3.3.1. Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Product Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. Charles River Laboratories International, Inc.
      • 8.3.4.1. Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Product Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. PAREXEL International Corp.
      • 8.3.5.1. Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Product Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Syneos Health
      • 8.3.6.1. Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Product Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. Medpace Holdings, Inc.
      • 8.3.7.1. Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Product Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. PPD Inc.
      • 8.3.8.1. Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Product Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Novotech
      • 8.3.9.1. Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Product Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. Veristat, LLC.
      • 8.3.10.1. Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Product Benchmarking
      • 8.3.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Leading Market Players Anticipated to Witness Highest Growth
  • Table 4 Global RNA Therapy Clinical Trials Market, By Region, 2018 - 2030 (USD Million)
  • Table 5 Global RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 6 Global RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 7 Global RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 8 North America RNA Therapy Clinical Trials Market, By Country, 2018 - 2030 (USD Million)
  • Table 9 North America RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 10 North America RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 11 North America RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 12 U.S. RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 13 U.S. RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 14 U.S. RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 15 Canada RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 16 Canada RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 17 Canada RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 18 Europe RNA Therapy Clinical Trials Market, By Country, 2018 - 2030 (USD Million)
  • Table 19 Europe RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 20 Europe RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 21 Europe RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 22 UK RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 23 UK RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 24 UK RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 25 Germany RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 26 Germany RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 27 Germany RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 28 France RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 29 France RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 30 France RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 31 Italy RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 32 Italy RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 33 Italy RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 34 Spain RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 35 Spain RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 36 Spain RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 37 Sweden RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 38 Sweden RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 39 Sweden RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 40 Norway RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 41 Norway RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 42 Norway RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 43 Denmark RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 44 Denmark RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 45 Denmark RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific RNA Therapy Clinical Trials Market, By Country, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 50 Japan RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 51 Japan RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 52 Japan RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 53 China RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 54 China RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 55 China RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 56 India RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 57 India RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 58 India RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 59 Australia RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 60 Australia RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 61 Australia RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 62 South Korea RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 63 South Korea RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 64 South Korea RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 65 Thailand RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 66 Thailand RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 67 Thailand RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 68 Latin America RNA Therapy Clinical Trials Market, By Country, 2018 - 2030 (USD Million)
  • Table 69 Latin America RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 70 Latin America RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 71 Latin America RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 72 Brazil RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 73 Brazil RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 74 Brazil RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 75 Mexico RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 76 Mexico RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 77 Mexico RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 78 Argentina RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 79 Argentina RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 80 Argentina RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 81 Middle East and Africa RNA Therapy Clinical Trials Market, By Country, 2018 - 2030 (USD Million)
  • Table 82 Middle East and Africa RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 83 Middle East and Africa RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 84 Middle East and Africa RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 85 South Africa RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 86 South Africa RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 87 South Africa RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 90 Saudi Arabia RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 91 UAE RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 92 UAE RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 93 UAE RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 94 Kuwait RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 95 Kuwait RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 96 Kuwait RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 RNA Therapy Clinical Trials Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market outlook (2022)
  • Fig. 10 Strategy framework
  • Fig. 11 Market driver relevance analysis (Current & future impact)
  • Fig. 12 Market restraint relevance analysis (Current & future impact)
  • Fig. 13 Penetration & growth prospect mapping
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 PESTLE analysis
  • Fig. 16 RNA Therapy Clinical Trials Market: Modality movement analysis
  • Fig. 17 RNA Therapy Clinical Trials Market: Modality segment dashboard
  • Fig. 18 RNA Therapy Clinical Trials Market Modality outlook: Key takeaways
  • Fig. 19 RNA interference market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Antisense therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Messenger RNA market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Oligonucleotide, non-antisense, non-RNAi market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 RNA Therapy Clinical Trials Market: Clinical Trials Phase movement analysis
  • Fig. 24 RNA Therapy Clinical Trials Market: Clinical Trials Phase segment dashboard
  • Fig. 25 RNA Therapy Clinical Trials Market: Clinical Trials Phase outlook: Key takeaways
  • Fig. 26 Phase I market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Phase II market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Phase III market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Phase IV market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 RNA Therapy Clinical Trials Market: Therapeutic Areas movement analysis
  • Fig. 31 RNA Therapy Clinical Trials Market: Therapeutic Areas segment dashboard
  • Fig. 32 RNA Therapy Clinical Trials Market: Therapeutic Areas outlook: Key takeaways
  • Fig. 33 Rare Diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Anti-infective market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Anticancer market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Neurological market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Alimentary/Metabolic market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Musculoskeletal market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Cardiovascular Respiratory market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Sensory market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Global RNA Therapy Clinical Trials market, 2018 - 2030 (USD Million)
  • Fig. 43 North America RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 44 U.S. RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 45 Canada RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 46 Europe RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 47 UK RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 48 Germany RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 49 France RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 50 Italy RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 51 Spain RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 52 Sweden RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 53 Norway RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 54 Denmark RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 55 Asia Pacific RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 56 Japan RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 57 China RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 58 India RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 59 Australia RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 60 South Korea RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 61 Thailand RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 62 Latin America RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 63 Brazil RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 64 Mexico RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 65 Argentina RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 66 MEA RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 67 South Africa RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 68 Saudi Arabia RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 69 UAE RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 70 Kuwait RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 71 Heat map analysis
  • Fig. 72 Market differentiator